Study: NCT05245396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T1
Description: Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T1
Description: Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T1
Description: Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T1
Description: Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T1
Description: Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T2
Description: Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T2
Description: Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T2
Description: Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T3
Description: Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T3
Description: Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T3
Description: Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T4
Description: Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T4
Description: Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T4
Description: Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C1
Description: Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C1
Description: Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C1
Description: Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C2
Description: Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C2
Description: Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C2
Description: Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C3
Description: Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C3
Description: Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C3
Description: Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C4
Description: Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C4
Description: Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C4
Description: Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T adapated
Description: Participants will receive single oral dose of MR-T adapted on Day 1 in treatment period 1, 2, and 3 of Part D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T adapated
Description: Participants will receive single oral dose of MR-T adapted on Day 1 in treatment period 1, 2, and 3 of Part D.